ScreenerHero

MSLE Satellos Bioscience Inc.

NAS · US · Healthcare · Biotechnology · satellos.com
7.630USD+1.19%Mkt Cap: 161.88M $P/E: —

Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company us…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap161.88M USD
Enterprise Value98.13M USD
Revenue (TTM)—
Gross Profit-9.48M USD
Net Income (TTM)-24.87M USD
Revenue/Share—
Last Price7.630 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees18
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.75
PEG—
EV/EBITDA-2.74
EV/Revenue—
P/S—
P/B2.62
EPS (TTM)-1.95
EPS (Forward)-2.74
52W Range
5.30429% of range13.39
52W High13.39 USD
52W Low5.304 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-89.52%
ROA-78.00%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-23.60M USD
CapEx (TTM)6.00K USD
FCF Margin—
FCF Yield-10.45%
Net Debt-61.84M USD
Net Debt/EBITDA1.73
Balance Sheet
Debt/Equity—
Current Ratio11.22
Quick Ratio10.69
Book Value/Sh2.88 USD
Cash/Share2.92 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:12
Split DateJan 30, 2026
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)26.25 USD
Upside (mean)+244.0%
Target Range20.00 USD – 40.00 USD
20.00+244.0% to mean40.00
# Analysts4
Ownership
Shares Out.21.22M
Float18.02M
Insiders6.37%
Institutions49.70%
Short Interest
Short Ratio3.1d
Short % Out.0.39%
Shares Short82.43K
Short (prev mo.)91.67K
Technical
SMA 509.414 (-19.0%)
SMA 2008.438 (-9.6%)
Beta1.15
S&P 52W Chg15.78%
Avg Vol (30d)47.74K
Avg Vol (10d)85.13K
Technical Indicators
RSI (14)29.7
MACD-0.3992
MACD Signal-0.2601
MACD Hist.-0.1392
BB Upper10.30 USD
BB Middle8.873 USD
BB Lower7.444 USD
BB Width32.21%
ATR (14)0.5438 USD
Vol Ratio (20d)0.78x